PharmiWeb.com - Global Pharma News & Resources
30-Sep-2024

Xlife Sciences AG enables international co-investors to enter the stock and is planning a dual listing on the London Stock Exchange Group (LSEG)

Xlife Sciences AG / Key word(s): Alliance/Strategic Company Decision

30-Sep-2024 / 20:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Zurich, 30th of September 2024: The management of Xlife Sciences AG (SIX:XLS) was commissioned on September 3, 2024, after an intensive review of all available options and offers from the Board of Directors, to implement a strategy to increase market capitalization and, consequently, the stock price, as well as the liquidity and tradability of the stock.

In close coordination with new international co-investors, a dual listing on the London Stock Exchange Group (LSEG) is being developed as the first step towards implementing the value enhancement and growth strategy, and it will be executed promptly in cooperation with investment banks, funds, and market makers.

Xlife Sciences AG is confident that this will provide our valued shareholders with the greatest added value in the short term. Additionally, the company is tapping into an important, international, and continuously growing investor base, which not only enables the ambitious growth targets to be achieved but also helps align the discrepancy between market capitalization and valuation.

The Swiss Exchange (SIX Group) has already established the necessary foundation for this with the introduction of stock equivalence with the London Stock Exchange Group (LSEG).

Xlife Sciences AG would like to sincerely thank its investors for their trust and patience.

Financial calendar

Annual Report 2024 25 April 2025
Annual Shareholders Meeting 2025 24 June 2025
Half-Year Report 2025 23 September 2025

Contact 
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch

Xlife Sciences AG, 
Talacker 35, 
8001 Zurich, 
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch
Commercial Register Zurich CHE-330.279.788 
Stock Exchange: SIX Swiss Exchange



End of Inside Information
Language: English
Company: Xlife Sciences AG
Talacker 35
8001 Zürich
Switzerland
Phone: +41 44 385 84 60
E-mail: info@xlifesciences.ch
Internet: www.xlifesciences.ch
ISIN: CH0461929603
Valor: A2PK6Z
Listed: SIX Swiss Exchange
EQS News ID: 1998973

 
End of Announcement EQS News Service

Editor Details

Last Updated: 30-Sep-2024